Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma
2018 · Journal of Clinical Oncology · 252 citations
https://doi.org/10.1200/jco.18.00545
T
Toshitaka Nagao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
365
Papers
8.8K
Citations
49
h-index
157
i10-index
Toshitaka Nagao is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Salivary Gland Tumors Diagnosis and Treatment & Ear and Head Tumors & Oral and Maxillofacial Pathology. The author has an h-index of 49, co-authored 311 publications.
ORCID: 0000-0003-2075-9738Papers by this author
worksInvasive Micropapillary Salivary Duct Carcinoma
2004 · The American Journal of Surgical Pathology · 182 citations
https://doi.org/10.1097/00000478-200403000-00004
“Dedifferentiation” and High-Grade Transformation in Salivary Gland Carcinomas
2013 · Head and Neck Pathology · 147 citations
https://doi.org/10.1007/s12105-013-0458-8
Dedifferentiated Adenoid Cystic Carcinoma: A Clinicopathologic Study of 6 Cases
2003 · Modern Pathology · 135 citations
https://doi.org/10.1097/01.mp.0000097366.88165.08
Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients
2016 · Annals of Surgical Oncology · 104 citations
https://doi.org/10.1245/s10434-015-5082-2
Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
2021 · Scientific Reports · 90 citations
https://doi.org/10.1038/s41598-021-87575-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat